Chapter 4. Development of Agents that Selectively Disrupt Tumor Vasculature: A Historical Perspective
- Dietmar W. Siemann3,4
Published Online: 31 MAY 2006
DOI: 10.1002/0470035439.ch4
Copyright © 2006 John Wiley & Sons, Ltd
Book Title
Vascular-Targeted Therapies in Oncology
Additional Information
How to Cite
Chaplin, D. J. and Hill, S. A. (2006) Development of Agents that Selectively Disrupt Tumor Vasculature: A Historical Perspective, in Vascular-Targeted Therapies in Oncology (ed D. W. Siemann), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470035439.ch4
Editor Information
- 3
Shands Cancer Center, University of Florida, Gainsville, Florida, USA
- 4
Research Department of Radiation Oncology, University of Florida, 2000 RW Archer Road, Gainsville, FL 32610, USA
Publication History
- Published Online: 31 MAY 2006
- Published Print: 10 MAR 2006
ISBN Information
Print ISBN: 9780470012949
Online ISBN: 9780470035436
- Summary
- Chapter
Keywords:
- antiangiogenic therapies;
- small-molecule-based VDAs;
- vascular occlusion on tumor cell survival;
- VDA therapeutics;
- VDA - flavone acetic acid (FAA);
- N-cadherin antagonists;
- tubulin depolymerizing agents;
- tubulin binding activity;
- tumor vasculature - potential therapeutic target
Summary
This chapter contains sections titled:
Introduction
Early history
Formulation of the VDA concept
Effects of vascular occlusion on tumor cell survival
Rational development of VDA therapeutics
Development of small-molecule VDAs
Combretastatin A4 phosphate
The viable rim
Conclusions
References